• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Section 32 Raises $740 Million Venture Fund

    11/4/21 8:14:00 AM ET
    $COIN
    $CRWD
    $EXAS
    $RLAY
    Finance: Consumer Services
    Finance
    Computer Software: Prepackaged Software
    Technology
    Get the next $COIN alert in real time by email

    SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Section 32 announced today the closing of its fourth fund, raising approximately $740 million from returning and new investors. Investors in Fund 4 include leading philanthropic and non-profit organizations, educational endowments and foundations, and leaders from the technology and healthcare sectors. Section 32 Fund 4 will support companies across all stages that are pioneering innovations at the forefront of technology and healthcare. With the closing of its oversubscribed Fund 4 and to support its continued growth, Section 32 also announced the appointment of Nina Labatt to the role of Chief Operating Officer and Chief Financial Officer.

    Section 32 is a venture capital fund investing at the frontiers of technology and healthcare.

    "I'm so pleased that Nina has joined this team and I look forward to what this growing group will achieve together," commented Bill Maris, founder of Section 32. "What a privilege it is to close this fourth fund, and to thus have the continued opportunity to try to use capital as a lever to accelerate the profound positive impact technology can have on healthcare and humanity."

    The closing of Fund 4 brings assets under management for Section 32 to over $1.8B. To-date, Section 32 has made investments in more than 70 companies including Coinbase (NASDAQ:COIN), Crowdstrike (NASDAQ:CRWD), Relay Therapeutics (NASDAQ:RLAY), Thrive Earlier Detection (NASDAQ:EXAS), and Vir Biotechnology (NASDAQ:VIR). Section 32 has made eight investments from Fund 4 following an initial close of the fund in July 2021.

    Since its inception in 2017, Section 32 has grown to 16 people, including four managing partners: Bill Maris, Michael Pellini, M.D., Steve Kafka, Ph.D., and Andy Harrison, with offices in San Diego, Silicon Valley and Boston, MA. The team's cumulative career experience includes contributing to more than 130 company exits (through acquisition or public offerings) and helping to build and finance more than 50 companies with valuations in excess of $1 billion.

    With the closing of Fund 4, Section 32 added Nina Labatt to its team as its chief operating officer and chief financial officer. Nina brings more than two decades of experience to her new role and is recognized as an industry expert leading finance and operations in venture capital and private equity.

    "I'm delighted to join the team at Section 32 at this exciting time in the firm's growth," commented Nina Labatt. "I look forward to collaborating with the team to continue building world-class operations and finance functions that support our investing efforts."

    Most recently, Nina served as chief operating officer and general partner at Trinity Ventures, where she managed finance, marketing, data analytics, human resources, and legal for the firm. She also led internal strategic initiatives, structured and executed investment transactions with the investing team and participated in the firm's fundraising efforts. Previously, Ms. Labatt served as managing director, Private Equity Services for Silicon Valley Bank, as well as chief financial officer for Health Evolution Partners. Earlier in her career, Ms. Labatt was an investment banker for Goldman Sachs and Montgomery Securities. Ms. Labatt received a bachelor's degree in economics and a master's degree in international policy studies from Stanford University. She received her MBA from Harvard Business School. She was a founding member of the Northern California board of directors for the CFO Leadership Council and previously served as chairperson of the board of directors of VCBC, a non-profit association for finance professionals in venture capital.

    About Section 32

    Section 32 is a venture capital fund investing at the frontiers of technology and healthcare. Founded by Bill Maris, the team has vast experience building iconic companies. The firm's goal is to improve the human condition by accelerating the discovery, development and distribution of important technologies and life-saving medicines. Section 32 invests across the entirety of technology and life sciences. This includes software, cybersecurity, advanced communications and computation, space, climate change related technologies, machine learning, artificial intelligence, biotechnology, therapeutics, advanced diagnostics, precision medicine, genomics and more. For more information, please visit Section32.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/section-32-raises-740-million-venture-fund-301416494.html

    SOURCE Section 32

    Get the next $COIN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COIN
    $CRWD
    $EXAS
    $RLAY

    CompanyDatePrice TargetRatingAnalyst
    Coinbase Global Inc.
    $COIN
    1/28/2026$240.00Neutral
    Robert W. Baird
    Coinbase Global Inc.
    $COIN
    1/27/2026$277.00Overweight
    Cantor Fitzgerald
    Relay Therapeutics Inc.
    $RLAY
    1/26/2026$14.00Perform → Outperform
    Oppenheimer
    Exact Sciences Corporation
    $EXAS
    1/20/2026$105.00Outperform → Neutral
    Mizuho
    CrowdStrike Holdings Inc.
    $CRWD
    1/12/2026Overweight → Sector Weight
    KeyBanc Capital Markets
    CrowdStrike Holdings Inc.
    $CRWD
    1/9/2026$600.00Hold → Buy
    Berenberg
    Coinbase Global Inc.
    $COIN
    1/8/2026$340.00Neutral → Buy
    BofA Securities
    Exact Sciences Corporation
    $EXAS
    1/5/2026$105.00Outperform → In-line
    Evercore ISI
    More analyst ratings

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Podbere Burt W. sold $714,472 worth of shares (1,630 units at $438.33), decreasing direct ownership by 0.91% to 177,484 units (SEC Form 4)

    4 - CrowdStrike Holdings, Inc. (0001535527) (Issuer)

    2/3/26 8:00:08 PM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    PRESIDENT AND CEO Kurtz George sold $2,972,389 worth of shares (6,777 units at $438.60), decreasing direct ownership by 0.32% to 2,083,755 units (SEC Form 4)

    4 - CrowdStrike Holdings, Inc. (0001535527) (Issuer)

    2/3/26 8:00:06 PM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    Director Sato Vicki L sold $169,671 worth of shares (22,000 units at $7.71), decreasing direct ownership by 2% to 1,144,391 units (SEC Form 4)

    4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

    2/3/26 12:28:45 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $COIN
    $CRWD
    $EXAS
    $RLAY
    SEC Filings

    View All

    Relay Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Relay Therapeutics, Inc. (0001812364) (Filer)

    2/3/26 7:10:25 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Exact Sciences Corporation

    DEFA14A - EXACT SCIENCES CORP (0001124140) (Filer)

    1/30/26 4:01:09 PM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by Exact Sciences Corporation

    DEFA14A - EXACT SCIENCES CORP (0001124140) (Filer)

    1/23/26 6:03:01 AM ET
    $EXAS
    Medical Specialities
    Health Care

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Conroy Kevin T bought $1,001,325 worth of shares (19,500 units at $51.35), increasing direct ownership by 2% to 1,074,191 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    11/13/24 12:56:28 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Robert W. Baird initiated coverage on Coinbase Global with a new price target

    Robert W. Baird initiated coverage of Coinbase Global with a rating of Neutral and set a new price target of $240.00

    1/28/26 7:16:37 AM ET
    $COIN
    Finance: Consumer Services
    Finance

    Cantor Fitzgerald resumed coverage on Coinbase Global with a new price target

    Cantor Fitzgerald resumed coverage of Coinbase Global with a rating of Overweight and set a new price target of $277.00

    1/27/26 8:44:53 AM ET
    $COIN
    Finance: Consumer Services
    Finance

    Relay Therapeutics upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Relay Therapeutics from Perform to Outperform and set a new price target of $14.00

    1/26/26 8:32:07 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

    CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 10:30 a.m. ET. The fireside chats will be webcast live and may be accessed through Relay Therapeutics' website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be availa

    2/4/26 4:05:00 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Institutional-Grade Token Architecture Positions Companies at the Center of Digital Finance

    Scalable, compliant infrastructure supports demand for regulated digital assets for growing number of industries  Market News Updates News Commentary NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Digital finance is moving fast, and institutional-grade token architecture is becoming a core piece of the financial system. Large investors and institutions want digital assets that are secure, compliant, and easy to integrate with traditional finance. Tokenized infrastructure built for institutions helps make that possible by supporting regulated transactions, asset-backed tokens, and scalable platforms designed for real-world use, not just experimentation as Active Companies take notice that may include

    2/4/26 8:45:00 AM ET
    $COIN
    $DJT
    $GNLN
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology

    Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests

    Passage of MCED legislation marks major milestone for early cancer detection Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today celebrated the passage of landmark federal legislation that establishes a pathway to enable Medicare coverage for multi-cancer early detection (MCED) tests. Nearly 70% of annual cancer cases and deaths in the U.S. occur in cancers with no recommended screening,1,2 and cancer remains the second leading cause of death in the U.S.1 By aligning public policy with scientific innovation and patient need, this legislation represents a critical step toward addressing that unmet need and expanding access to this emerging

    2/3/26 2:32:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    CrowdStrike Appoints Andy Nowinski as Vice President of Investor Relations and Strategic Finance

    CrowdStrike (NASDAQ:CRWD) today announced Andy Nowinski as Vice President of Investor Relations and Strategic Finance. Andy now leads the company's investor relations strategy, strengthening engagement with the global investment community and driving strategic financial initiatives that support the company's long-term growth as CrowdStrike advances its position as the industry's first hyperscaler of security. "Andy's blend of investment acumen, technical depth, and sector expertise makes him uniquely qualified for this role," said Burt Podbere, CFO of CrowdStrike. "His disciplined understanding of market structure, operating performance, and the long-term drivers of cybersecurity will ensu

    12/2/25 8:05:00 AM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Coinbase Global Inc.

    SC 13G/A - Coinbase Global, Inc. (0001679788) (Subject)

    11/14/24 5:44:24 PM ET
    $COIN
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by Coinbase Global Inc.

    SC 13G/A - Coinbase Global, Inc. (0001679788) (Subject)

    11/14/24 5:40:50 PM ET
    $COIN
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by CrowdStrike Holdings Inc.

    SC 13G/A - CrowdStrike Holdings, Inc. (0001535527) (Subject)

    11/14/24 1:22:38 PM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Financials

    Live finance-specific insights

    View All

    Institutional-Grade Token Architecture Positions Companies at the Center of Digital Finance

    Scalable, compliant infrastructure supports demand for regulated digital assets for growing number of industries  Market News Updates News Commentary NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Digital finance is moving fast, and institutional-grade token architecture is becoming a core piece of the financial system. Large investors and institutions want digital assets that are secure, compliant, and easy to integrate with traditional finance. Tokenized infrastructure built for institutions helps make that possible by supporting regulated transactions, asset-backed tokens, and scalable platforms designed for real-world use, not just experimentation as Active Companies take notice that may include

    2/4/26 8:45:00 AM ET
    $COIN
    $DJT
    $GNLN
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology

    CrowdStrike Announces Date of Fourth Quarter and Fiscal Year 2026 Financial Results Conference Call

    CrowdStrike Holdings, Inc. (NASDAQ:CRWD), today announced that it will release financial results for its fourth quarter and fiscal year 2026 ended January 31, 2026 after the U.S. market close on Tuesday, March 3, 2026. CrowdStrike will host a conference call that day at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) to discuss the results. To register for the live event please visit https://crowdstrike-fiscal-fourth-quarter-2026-results-conference-call.open-exchange.net/ A live webcast of the conference call and the financial results press release will be accessible from the CrowdStrike investor relations website at ir.crowdstrike.com. An audio webcast replay of the conference call wil

    2/3/26 8:30:00 AM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    Coinbase Announces Date of Fourth Quarter and Full Year 2025 Financial Results

    Coinbase Global, Inc. (the "Company" or "Coinbase") announced today that it will release its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, after market close. The Company will hold a webcast to discuss its financial results at 2:30 p.m. PT that same day. The live webcast of the call can be accessed here. Following the call, a replay of the call, as well as a transcript, will be available on the Investor Relations website at investor.coinbase.com. Disclosure Information In addition to filings with the Securities and Exchange Commission, the Company uses its Investor Relations website (investor.coinbase.com), its blog (blog.coinbase.com), press rele

    1/16/26 8:00:00 AM ET
    $COIN
    Finance: Consumer Services
    Finance